StemCell Therapy

March 1 Puma Biotechnology Inc:

* Puma Biotechnology provides update on review of marketing authorisation application for PB272

* Puma Biotechnology Inc - company plans to modify summary of product characteristics in its marketing authorisation application

* Puma Biotechnology-plans to modify summary of product characteristics based on meeting with rapporteur, co-rapporteur, review team members, EMA

* Puma Biotechnology - proposed summary of product characteristics will continue to include both hormone receptor positive, hormone receptor negative patients

* Puma-Will be revising proposed smpc for neratinib to restrict intended population to patients within a year after completion of Adjuvant Trastuzumab Therapy

* Puma-Committee for medicinal products for human use continuing to review co's maa and has not yet made a final decision to recommend approval of drug Source text for Eikon: Further company coverage:

BRUSSELS, March 2 Anheuser-Busch InBev, the world's largest brewer, raised its forecast for savings from its near $100 billion takeover of SABMiller after weaker than expected earnings as beer sales suffered in Brazil.

TOKYO, March 2 Japan's Nikkei share average hit a 14-month peak on Thursday as the yen weakened against the dollar on heightened expectations for the Federal Reserve to raise interest rates this month and after Wall Street soared to record highs.

* Acquired privately held Ontology Systems for a total consideration of US$7.6 million, net of cash

More:
BRIEF-Puma Biotechnology provides update on review of marketing authorisation application for PB272 - Reuters

This entry was posted on March 2, 2017 at 1:53 am and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |